Literature DB >> 27709475

Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy.

Valentina Zilioli1, Alessia Peli1, Maria Beatrice Panarotto1, Giancarlo Magri1, Ahmed Alkraisheh1, Christiane Wiefels2, Carlo Rodella3, Raffaele Giubbini4,5.   

Abstract

The purpose of this prospective study was to determine the incremental diagnostic value of single photon emission computed tomography/computed tomography with iodine-131 over planar whole body scan in the staging of patients with differentiated thyroid carcinoma. A total of 365 patients (270 female, 95 male) with differentiated thyroid carcinoma were treated with radioiodine therapy for thyroid remnant ablation with radical intent after thyroidectomy between January 2013 and November 2014. In addition to planar whole body scan, single photon emission computed tomography/computed tomography of neck and chest were performed. Each radioactive focus at whole body scan was classified as positive or equivocal with respect of specific territories: thyroid bed, cervical lymph nodes and distant metastases.Whole-body scan detected focal uptake in 353 patients and no uptake in 12. The location was considered equivocal in 100. Single photon emission computed tomography/computed tomography detected focal uptake in 356 patients and no uptake in nine. In three patients with negative wholebody scan, single photon emission computed tomography/computed tomography provided information about residual activity in the thyroid bed. By single photon emission computed tomography/computed tomography the location was equivocal in 18 patients only. Single photon emission computed tomography/computed tomography was helpful in 82 out of 100 patients with equivocal findings by whole body scan allowing a correct identification of the uptake sites. In a great number of equivocal whole body scan, due to high remnant activity, single photon emission computed tomography/computed tomography was able to differentiate between thyroid remnant and lymph nodes uptake. In 22 out of 100 patients with doubtful whole body scan, single photon emission computed tomography/computed tomography correctly identified nodal or distant metastases, and in 2/100 patients, focal uptake classified as metastatic by whole body scan was reclassified as para-physiological by single photon emission computed tomography/computed tomography. The TNM classification changed in 13 out of 22 patients. Single photon emission computed tomography/computed tomography improves detection and localization of the iodine-131 uptake after thyroidectomy in patients with differentiated thyroid carcinoma and it is more accurate than whole body scan to evaluate lymph nodes and to identify and characterize distant metastases. Single photon emission computed tomography/computed tomography aids assessment of lower/upper stage in a significant number of patients with differentiated thyroid carcinoma and it can affect therapy decision-making and patient management.

Entities:  

Keywords:  131-I; Differentiated Thyroid cancer; SPECT/CT; Staging; Whole body scan

Mesh:

Substances:

Year:  2016        PMID: 27709475     DOI: 10.1007/s12020-016-1086-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  29 in total

Review 1.  Isotope imaging for metastatic thyroid cancer.

Authors:  B R Haugen; E C Lin
Journal:  Endocrinol Metab Clin North Am       Date:  2001-06       Impact factor: 4.741

2.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

3.  Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.

Authors:  Yasuhiro Maruoka; Koichiro Abe; Shingo Baba; Takuro Isoda; Hirofumi Sawamoto; Yoshitaka Tanabe; Masayuki Sasaki; Hiroshi Honda
Journal:  Radiology       Date:  2012-09-25       Impact factor: 11.105

4.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

5.  Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer.

Authors:  Nicolas Aide; Natacha Heutte; Jean-Pierre Rame; Elise Rousseau; Cédric Loiseau; Michel Henry-Amar; Stéphane Bardet
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

6.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

7.  Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma.

Authors:  K Tharp; O Israel; J Hausmann; L Bettman; W H Martin; M Daitzchman; M P Sandler; D Delbeke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-19       Impact factor: 9.236

8.  Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases.

Authors:  M Filesi; A Signore; G Ventroni; F F Melacrinis; G Ronga
Journal:  J Nucl Med       Date:  1998-09       Impact factor: 10.057

9.  Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma.

Authors:  Ka Kit Wong; Natalia Zarzhevsky; John M Cahill; Kirk A Frey; Anca M Avram
Journal:  AJR Am J Roentgenol       Date:  2008-12       Impact factor: 3.959

10.  Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen.

Authors:  S Kohlfuerst; I Igerc; M Lobnig; H J Gallowitsch; I Gomez-Segovia; S Matschnig; J Mayr; P Mikosch; M Beheshti; P Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-24       Impact factor: 9.236

View more
  8 in total

1.  To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment.

Authors:  Murat Tuncel; Alexis Vrachimis; Alfredo Campenni; Bart de Keizer; Frederik A Verburg; Michael C Kreissl; Petra Petranovic Ovcaricek; Tamara Geliashvili; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08       Impact factor: 10.057

2.  I-131 Postablation SPECT/CT Predicts Relapse of Papillary Thyroid Carcinoma more Accurately than Whole Body Scan.

Authors:  Julia V Malamitsi; John T Koutsikos; Stamatia I Giourgouli; Sophia F Zachaki; Theodoros A Pipikos; Fani J Vlachou; Vassilios K Prassopoulos
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

Review 3.  Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence.

Authors:  Ora Israel; O Pellet; L Biassoni; D De Palma; E Estrada-Lobato; G Gnanasegaran; T Kuwert; C la Fougère; G Mariani; S Massalha; D Paez; F Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

4.  Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.

Authors:  Shingo Iwano; Shinji Ito; Shinichiro Kamiya; Rintaro Ito; Katsuhiko Kato; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2020-05       Impact factor: 1.131

5.  The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on 131I-SPECT/CT.

Authors:  Feng Wang; Hui Nie; Wei Li; Rusen Zhang; Wen Li
Journal:  BMC Med Imaging       Date:  2021-05-08       Impact factor: 1.930

6.  Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis.

Authors:  Shang Lin; Ya-Ru Wei; Hong-Xiang Yao
Journal:  Int J Gen Med       Date:  2021-12-14

7.  Clinical experience following implementation of routine SPECT-CT imaging following 131-iodine administration for thyroid cancer.

Authors:  Sara Ahmadi; Alexandra Coleman; Nathalie Silva de Morais; Iñigo Landa; Theodora Pappa; Alex Kang; Matthew I Kim; Ellen Marqusee; Erik K Alexander
Journal:  Endocr Connect       Date:  2022-05-25       Impact factor: 3.221

Review 8.  Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.

Authors:  Cristina Barca; Christoph M Griessinger; Andreas Faust; Dominic Depke; Markus Essler; Albert D Windhorst; Nick Devoogdt; Kevin M Brindle; Michael Schäfers; Bastian Zinnhardt; Andreas H Jacobs
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.